Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Gene therapy with lentiviral vectors targeting transgene expression to hepatocytes provides stable reconstitution of clotting activity in dogs with hemophilia B and does not show genotoxicity in tumor-prone mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [79]
Experimental — accuracy not yet measuredIn the citing paper
“Although AAV efforts predominate, lentiviral vectors for either systemic infusion157,158 or ex vivo transduction of hematopoietic stem cells159, 160, 161 or induced pluripotent stem cells162 are being pursued preclinically or as a phase I clinical trial.156”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Self-citationHepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777 · cited 1×
“CCl4 administration results in waves of hepatocytes necrosis and regeneration that cause liver damage (41).”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180 · cited 5×
“We produced three large-scale batches of lentiviral vectors according to a manufacturing process previously developed for clinical-grade lentiviral vectors (19, 20).”
BackgroundMethodSelf-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025 · cited 4×
“The vector batches were produced by using a large-scale validated process (19, 20) and following pre-GMP guidelines.”
BackgroundMethodSelf-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“However, there are still important hurdles to overcome before this gene therapy can be applied to the majority of severely affected patients (9).”
BackgroundBolton-Maggs, P. H., & Pasi, K. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13405-8 · Cited by 763 · cited 1×
“Hemophilia is a monogenic X-linked disease caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) (1).”
BackgroundMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701
Self-citationAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571 · cited 3×
“The safe outcome of these trials to date supports the predictions about vector safety developed in our preclinical tumor-prone mouse models, where the consequences of insertional mutagenesis are amplified in a model species that otherwise limits detection of low incidence, vector-induced oncogenesis (21, 22).”
BackgroundSelf-citationGene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
Self-citationBrown, B. D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., & Naldini, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1372 · Cited by 556
Self-citationBrown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Self-citationX-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394 · cited 2×
“The lentiviral vectors contained the wildtype, codon-usage optimized, or codon-usage optimized hyper-functional cFIX carrying the R338L mutation associated with human thrombophilia (cFIX, co-cFIX, co-cFIXR338L, respectively) (14, 23).”
BackgroundMethodBerntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335 · cited 1×
“Prophylactic or on-demand replacement therapy with recombinant products is the current standard of care for hemophilia in high-income countries and has improved the quality of life and life expectancy of patients with severe hemophilia (3).”
BackgroundHigh-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR)
Schmidt, M., Schwarzwaelder, K., Bartholomae, C., Zaoui, K., Ball, C., Pilz, I., Braun, S., Glimm, H., & von Kalle, C. (2007) · Nature Methods · doi:10.1038/nmeth1103 · Cited by 328
Self-citationPast, present and future of hemophilia: a narrative review
Franchini, M., & Mannucci, P. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-24 · Cited by 281 · cited 1×
“Moreover, about 80% of people affected by hemophilia live with no or unsatisfactory treatment, mainly in developing countries (5).”
BackgroundA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Self-citationThemis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243
Self-citationVSV-G Pseudotyped Lentiviral Vector Particles Produced in Human Cells Are Inactivated by Human Serum
DePolo, N. J., Reed, J. D., Sheridan, P. L., Townsend, K., Sauter, S. L., Jolly, D. J., & Dubensky, T. W. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0116 · Cited by 220
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216 · cited 1×
“In contrast, lentiviral vector CIS often result from intrinsic biases of viral integration that preferentially target gene-dense genomic regions (26).”
BackgroundSelf-citationBrown, B. D., Sitia, G., Annoni, A., Hauben, E., Sergi, L. S., Zingale, A., Roncarolo, M. G., Guidotti, L. G., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2006-10-049312 · Cited by 188 · cited 2×
“genotoxic mutations conferred by the Cdkn2a deficiency (21, 22) to the increased permissiveness to liver gene transfer by lentiviral vectors conferred by the Ifnar1 deficiency (28).”
BackgroundResultSelf-citationA factor IX-deficient mouse model for hemophilia B gene therapy
Wang, L., Zoppè, M., Hackeng, T. M., Griffin, J. H., Lee, K.-F., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11563 · Cited by 164 · cited 2×
“Inder Verma at the Salk Institute (39).”
A New-Generation Stable Inducible Packaging Cell Line for Lentiviral Vectors
Farson, D. A., Witt, R. M., MCGUINNESS, R. P., Dull, T., Kelly, M., Song, J., Radeke, R., Bukovsky, A., Consiglio, A., & Naldini, L. (2001) · Human Gene Therapy · doi:10.1089/104303401750195935 · Cited by 160
Self-citationMátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
Self-citationINK4a-ARF alterations and p53 mutations in hepatocellular carcinomas
Tannapfel, A., Busse, C., Weinans, L., Benicke, M., Katalinic, A., Geißler, F., Hauss, J., & Wittekind, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204902 · Cited by 129
Lentiviral vector–based insertional mutagenesis identifies genes associated with liver cancer
Ranzani, M., Cesana, D., Bartholomae, C. C., Sanvito, F., Pala, M., Benedicenti, F., Gallina, P., Sergi, L. S., Merella, S., Bulfone, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2331 · Cited by 109
Self-citationHyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432591 · Cited by 101
Self-citationZanta, M.-A., Charrier, S., Brice-Ouzet, A., Martin, S., Opolon, P., Thrasher, A. J., Hope, T. J., & Galy, A. H. M. (2009) · Gene Therapy · doi:10.1038/gt.2009.3 · Cited by 97
Self-citationEscarpe, P. A., Zayek, N., Chin, P. S., Borellini, F., Zufferey, R., Veres, G., & Kiermer, V. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00167-9 · Cited by 90
Matsui, H., Hegadorn, C., Ozelo, M. C., Burnett, E., Tuttle, A., Labelle, A., McCray, P., Naldini, L., Brown, B. D., Hough, C., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.290 · Cited by 81
Self-citationde Sio, F. R. S., Cascio, P., Zingale, A., Gasparini, M., & Naldini, L. (2006) · Blood · doi:10.1182/blood-2005-10-4047 · Cited by 80 · cited 1×
“When data were %, Log Odds were calculated to perform tests assuming normal distribution (42).”
MethodSelf-citationSuerth, J. D., Maetzig, T., Brugman, M. H., Heinz, N., Appelt, J.-U., Kaufmann, K. B., Schmidt, M., Grez, M., Modlich, U., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.309 · Cited by 73
Self-citationCurrent status of haemophilia gene therapy
High, K. H., Nathwani, A., Spencer, T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 73
Nichols, T. C., Dillow, A. M., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Arruda, V. R., & High, K. A. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.144 · Cited by 73
Self-citationAnnoni, A., Cantore, A., Valle, P. D., Goudy, K., Akbarpour, M., Russo, F., Bartolaccini, S., D’Angelo, A., Roncarolo, M. G., & Naldini, L. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302857 · Cited by 63 · cited 1×
“In our prior studies of lentiviral vector gene therapy in mice with hemophilia B, we did not observe macroscopic liver lesions in the treated mice at necropsy (12, 14, 15).”
BackgroundSelf-citationVigna, E., Amendola, M., Benedicenti, F., Simmons, A. D., Follenzi, A., & Naldini, L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.11.017 · Cited by 60
Self-citationBinny, C., McIntosh, J., Peruta, M. D., Kymäläinen, H., Tuddenham, E. G. D., Buckley, S. M. K., Waddington, S. N., McVey, J. H., Spence, Y., Morton, C. L., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377630 · Cited by 58 · cited 1×
“suited for treatment of pediatric patients, in which hepatocyte turnover is high and episomal vectors may be progressively lost (10).”
BackgroundAstermark, J., Santagostino, E., & Hoots, W. K. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02294.x · Cited by 52 · cited 1×
“Nevertheless, this treatment has high costs and entails discomfort for patients and has the risk of inducing neutralizing anti-factor antibodies, which complicates further treatment (4).”
BackgroundGene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50 · cited 1×
“Gene therapy could help to address these needs by establishing long-term endogenous production of the clotting factor at therapeutic levels after a single treatment (2, 6, 7).”
BackgroundSelf-citationRussell, K. E., Olsen, E. H. N., Raymer, R. A., Merricks, E. P., Bellinger, D. A., Read, M. S., Rup, B. J., Keith, J. C., McCarthy, K. P., Schaub, R. G., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1498 · Cited by 39
Self-citationSchmitt, F., Remy, S., Dariel, A., Flageul, M., Pichard, V., Boni, S., Usal, C., Myara, A., Laplanche, S., Anegon, I., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.008 · Cited by 37
Real-Time Definition of Non-Randomness in the Distribution of Genomic Events
Abel, U., Deichmann, A., Bartholomae, C., Schwarzwaelder, K., Glimm, H., Howe, S., Thrasher, A., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000570 · Cited by 31 · cited 1×
“We applied standard criteria to identify genomic regions recurrently hit by lentiviral vector integrations with a frequency significantly higher than random, and defined them as Common Insertion Sites (CIS) (25).”
MethodSelf-citationAbsence of Circulating Factor IX Antigen in Hemophilia B Dogs of the UNC-Chapel Hill Colony
Herzog, R. W., Arrada, V., Fisher, T. R., Read, M. S., Nichols, T. C., & High, K. A. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614021 · Cited by 24 · cited 1×
“However, it should be noted that the dogs treated in this study, although totally devoid of circulating factor IX (29), do bear a missense mutation in their F9 gene and thus are not prone to developing anti-factor IX antibodies.”
BackgroundSelf-citationNowrouzi, A., Cheung, W., Li, T., Zhang, X., Arens, A., Paruzynski, A., Waddington, S. N., Osejindu, E., Reja, S., Kalle, C. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.224 · Cited by 24
Self-citationCondiotti, R., Goldenberg, D., Giladi, H., Perlman, T. S., Waddington, S. N., Buckley, S. M. K., Heim, D., Cheung, W., Themis, M., Coutelle, C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.193 · Cited by 19
Aouba, A., Dezamis, E., Sermet, A., ROTHSCHILD, C., Hermine, O., Lasne, D., & Torchet, M. ‐. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02089.x · Cited by 17
Nichols, T. C., Franck, H. W. G., Franck, C. T., de FRIESS, N., Raymer, R. A., & Merricks, E. P. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04613.x · Cited by 13
Self-citation
Cited by
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Self-citationClinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., & Lombardo, A. (2016) · Cell · doi:10.1016/j.cell.2016.09.006 · Cited by 516
“VSG-G pseudotyped LV stocks were prepared as previously described Cell 167, 219–232.e1–e6, September 22, 2016 e3 (Cantore et al., 2015).”
MethodSelf-citationRole of animal models in biomedical research: a review
Mukherjee, P., Roy, S., Ghosh, D., & Nandi, S. K. (2022) · Laboratory Animal Research · doi:10.1186/s42826-022-00128-1 · Cited by 502
Metadata
- Authors
- Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., Raymer, R., Merricks, E., Bellintani, F., Martin, S., Doglioni, C., D’Angelo, A., VandenDriessche, T., Chuah, M. K., Schmidt, M., Nichols, T., Montini, E., & Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- German Cancer Research Center (DE)
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- University of North Carolina at Chapel Hill (US)
- MolMed (Italy) (IT)
- Genethon (France) (FR)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Cantore, Alessio
- Ranzani, Marco
- Nichols, Timothy
- Montini, Eugenio
- Naldini, Luigi
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-04
- Volume
- 7
- Issue
- 277
- Pages
- 277ra28-277ra28
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5669486
- OpenAlex
- W2099852853
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 12 · 2023: 15 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 19 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 7
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- NIH (HL063098)
- European Union Seventh Framework Programme (222878-PERSIST)
- European Research Council Advanced
- Telethon (D3)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, lentiviral vectors, liver-directed gene therapy, canine model, insertional mutagenesis, genotoxicity, hepatocytes, coagulation factor IX, large animal model
- MeSH terms
- Animals, Blood Coagulation, Hemophilia B, Disease Models, Animal, Dogs, Female, Genetic Vectors, Liver, Mice, Inbred C57BL, Mutagens, Time Factors, Transduction, Genetic, Genetic Therapy, Lentivirus, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.